Community-onset Escherichia coli infection resistant to expanded-spectrum cephalosporins in low-prevalence countries

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 4, 2014, Pages 2126-2134

  Rogers, Benjamin A ^a   Ingram, Paul R ^b,c   Runnegar, Naomi ^d,e   Pitman, Matthew C ^f   Freeman, Joshua T ^g   Athan, Eugene ^h   Havers, Sally M ^a   Sidjabat, Hanna E ^a   Jones, Mark ^e   Gunning, Earleen ^e   De Almeida, Mary ^f   Styles, Kaylene ^h   Paterson, David L ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b ROYAL PERTH HOSPITAL   (Australia)

^c UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^d PRINCESS ALEXANDRA HOSPITAL   (Australia)

^e UNIVERSITY OF QUEENSLAND   (Australia)

^f ROYAL DARWIN HOSPITAL   (Australia)

^g AUCKLAND CITY HOSPITAL   (New Zealand)

^h Geelong Infectious Diseases Unit   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; CEFEPIME; CEFTAZIDIME; CEFTRIAXONE; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; COTRIMOXAZOLE; GENTAMICIN; MEROPENEM; NITROFURANTOIN; SULFAMETHOXAZOLE; TRIMETHOPRIM;

ADULT; AFRICA; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; AUSTRALIA AND NEW ZEALAND; BACTERIUM ISOLATE; BLOOD CULTURE; CASE CONTROL STUDY; CHINA; COMMUNICABLE DISEASE; CONTROLLED STUDY; CULTURAL ANTHROPOLOGY; DRUG EXPOSURE; DRUG USE; ESCHERICHIA COLI INFECTION; FEMALE; GENETIC RESISTANCE; HUMAN; HUMAN TISSUE; INDIA; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MIDDLE EAST; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; OCCUPATIONAL EXPOSURE; PHENOTYPE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK ASSESSMENT; TERTIARY CARE CENTER; TRAVEL; URINARY TRACT INFECTION;

ADULT; AGED; ANTI-BACTERIAL AGENTS; CEPHALOSPORINS; COMMUNITY-ACQUIRED INFECTIONS; DRUG RESISTANCE, BACTERIAL; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; RISK FACTORS;

EID: 84896909232     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02052-13     Document Type: Article

References (45)

1. Turnidge J, Gottlieb G, Mitchell D, Pearson J, Bell J, on behalf of The Australian Group on Antimicrobial Resistance. January 2012, posting date. Gram-negative survey, community-onset infections, 2010 antimicrobial susceptibility report. http://www.agargroup.org/files/ AGAR%20GNB10%20REAL%20FINAL.pdf.
2. European Centre for Disease Prevention and Control. 2012. Antimicrobial resistance surveillance in Europe 2011. Annual report of the European Antimicrobial Resistance Surveillance Network (EARS-Net). http://www.ecdc. europa.eu/en/publications/publications/antimicrobial-resistance-surveillance- europe-2011.pdf.
3. Doi Y, Park YS, Rivera JI, Adams-Haduch JM, Hingwe A, Sordillo EM, Lewis JS, II, Howard WJ, Johnson LE, Polsky B, Jorgensen JH, Richter SS, Shutt KA, Paterson DL. 2013. Community-associated extended-spectrum beta-lactamase- producing Escherichia coli infection in the United States. Clin. Infect. Dis. 56:641-648. http://dx.doi.org/10.1093/cid/cis942.
4. Looke DF, Gottlieb T, Jones CA, Paterson DL. 2013. Gram-negative resistance: can we combat the coming of a new "Red Plague"? Med. J. Aust. 198:243-244. http://dx.doi.org/10.5694/mja13.10190.
5. Cheng AC, Turnidge J, Collignon P, Looke D, Barton M, Gottlieb T. 2012. Control of fluoroquinolone resistance through successful regulation, Australia. Emerg. Infect. Dis. 18:1453-1460. http://dx.doi.org/10.3201/eid1809.111515.
6. Turnidge J. 1999. The use of antibiotics in food-producing animals: antibiotic-resistant bacteria in animals and humans. Commonwealth of Australia. http://www.health.gov.au/internet/main/publishing.nsf/Content/ health-pubs-jetacar-cnt.htm/$FILE/jetacar.pdf.
7. Australian Bureau of Statistics. 8 February 2010. International movements, Australia, December 2009. Document 3401.0: overseas arrivals and departures, Australia. Australian Bureau of Statistics, Canberra, Australia.
8. Hawser SP, Bouchillon SK, Hoban DJ, Badal RE, Hsueh PR, Paterson DL. 2009. Emergence of high levels of extended-spectrum-beta-lactamase-producing gram-negative bacilli in the Asia-Pacific region: data from the Study for Monitoring Antimicrobial Resistance Trends (SMART) program, 2007. Antimicrob. Agents Chemother. 53:3280-3284. http://dx.doi.org/10.1128/AAC.00426-09.
9. Lu PL, Liu YC, Toh HS, Lee YL, Liu YM, Ho CM, Huang CC, Liu CE, Ko WC, Wang JH, Tang HJ, Yu KW, Chen YS, Chuang YC, Xu Y, Ni Y, Chen YH, Hsueh PR. 2012. Epidemiology and antimicrobial susceptibility profiles of Gram-negative bacteria causing urinary tract infections in the Asia-Pacific region: 2009-2010 results from the Study for Monitoring Antimicrobial Resistance Trends (SMART). Int. J. Antimicrob. Agents 40(Suppl):S37-S43. http://dx.doi.org/10.1016/S0924- 8579(12)70008-0.
10. European Committee on Antimicrobial Susceptibility Testing. 2011. Clinical breakpoints-bacteria (v 1.3). European Committee on Antimicrobial Susceptibility Testing, Växjö, Sweden.
11. Clinical and Laboratory Standards Institute. 2011. Performance standards for antimicrobial susceptibility testing; 20th information supplement. CLSI document M100-S20. Clinical and Laboratory Standards Institute, Wayne, PA.
12. Charlson ME, Pompei P, Ales KL, MacKenzie CR. 1987. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J. Chronic Dis. 40:373-383. http://dx.doi.org/10.1016/0021-9681(87) 90171-8. (Pubitemid 17055592)
13. McCabe WR, Jackson GG. 1962. Gram-negative bacteremia. I. etiology and ecology. Arch. Intern. Med. 110:847-855. http://dx.doi.org/10.1001/archinte. 1962.03620240029006.
14. Kennedy K, Collignon P. 2010. Colonisation with Escherichia coli resistant to "critically important" antibiotics: a high risk for international travellers. Eur. J. Clin. Microbiol. Infect. Dis. 29:1501-1506. http://dx.doi.org/10.1007/s10096-010-1031-y.
15. Friedman ND, Kaye KS, Stout JE, McGarry SA, Trivette SL, Briggs JP, Lamm W, Clark C, MacFarquhar J, Walton AL, Reller LB, Sexton DJ. 2002. Health care-associated bloodstream infections in adults: a reason to change the accepted definition of community-acquired infections. Ann. Intern. Med. 137:791-797. http://dx.doi.org/10.7326/0003-4819-137-10-200211190-00007. (Pubitemid 35334450)
16. Sidjabat HE, Paterson DL, Adams-Haduch JM, Ewan L, Pasculle AW, Muto CA, Tian GB, Doi Y. 2009. Molecular epidemiology of CTX-M-producing Escherichia coli isolates at a tertiary medical center in western Pennsylvania. Antimicrob. Agents Chemother. 53:4733-4739. http://dx.doi.org/10.1128/AAC.00533-09.
17. Kojima A, Ishii Y, Ishihara K, Esaki H, Asai T, Oda C, Tamura Y, Takahashi T, Yamaguchi K. 2005. Extended-spectrum-beta-lactamase-producing Escherichia coli strains isolated from farm animals from 1999 to 2002: report from the Japanese Veterinary Antimicrobial Resistance Monitoring Program. Antimicrob. Agents Chemother. 49:3533-3537. http://dx.doi.org/10.1128/AAC.49.8. 3533-3537.2005. (Pubitemid 41060612)
18. Pasterán F, Rapoport M, Petroni A, Faccone D, Corso A, Galas M, Vázquez M, Procopio A, Tokumoto M, Cagnoni V. 2006. Emergence of PER-2 and VEB-1a in Acinetobacter baumannii strains in the Americas. Antimicrob. Agents Chemother. 50:3222-3224. http://dx.doi.org/10.1128/AAC.00284-06. (Pubitemid 44396446)
19. Sidjabat H, Silvey A, Paterson DL, Lim S. 2012. Development of Multiplex PCR: beta-lactamase genes and virulence determinants in E. coli, p 45. Abstr. Antimicrob. 2012, 13th Annu. Sci. Meet. Aust. Soc. Antimicrob., Brisbane, Australia.
20. Poirel L, Heritier C, Tolun V, Nordmann P. 2004. Emergence of oxacillinase-mediated resistance to imipenem in Klebsiella pneumoniae. Antimicrob. Agents Chemother. 48:15-22. http://dx.doi.org/10.1128/AAC.48.1.15- 22.2004. (Pubitemid 38040171)
21. Pitout JD, Campbell L, Church DL, Wang PW, Guttman DS, Gregson DB. 2009. Using a commercial DiversiLab semiautomated repetitive sequence-based PCR typing technique for identification of Escherichia coli clone ST131 producing CTX-M-15. J. Clin. Microbiol. 47:1212-1215. http://dx.doi.org/10.1128/JCM.02265- 08.
22. Wirth T, Falush D, Lan R, Colles F, Mensa P, Wieler LH, Karch H, Reeves PR, Maiden MC, Ochman H, Achtman M. 2006. Sex and virulence in Escherichia coli: an evolutionary perspective. Mol. Microbiol. 60:1136-1151. http://dx.doi.org/ 10.1111/j.1365-2958.2006.05172.x.
23. Ben-Ami R, Rodriguez-Bano J, Arslan H, Pitout JD, Quentin C, Calbo ES, Azap OK, Arpin C, Pascual A, Livermore DM, Garau J, Carmeli Y. 2009. A multinational survey of risk factors for infection with extended-spectrum beta-lactamase-producing enterobacteriaceae in nonhospitalized patients. Clin. Infect. Dis. 49:682-690. http://dx.doi.org/10.1086/604713.
24. Azap OK, Arslan H, Serefhanoglu K, Colakoglu S, Erdogan H, Timurkaynak F, Senger SS. 2010. Risk factors for extended-spectrum beta-lactamase positivity in uropathogenic Escherichia coli isolated from community-acquired urinary tract infections. Clin. Microbiol. Infect. 16:147-151. http://dx.doi.org/10.1111/j. 1469-0691.2009.02941.x.
25. Banerjee R, Strahilevitz J, Johnson JR, Nagwekar PP, Schora DM, Shevrin I, Du H, Peterson LR, Robicsek A. 2013. Predictors and molecular epidemiology of community-onset extended-spectrum beta-lactamase-producing Escherichia coli infection in a Midwestern community. Infect. Control Hosp. Epidemiol. 34:947-953. http://dx.doi.org/10.1086/671725.
26. Livermore DM, Hope R, Reynolds R, Blackburn R, Johnson AP, Woodford N. 2013. Declining cephalosporin and fluoroquinolone nonsusceptibility among bloodstream Enterobacteriaceae from the UK: links to prescribing change? J. Antimicrob. Chemother. 68:2667-2674. http://dx.doi.org/10.1093/jac/dkt212.
27. van der Bij AK, Pitout JD. 2012. The role of international travel in the worldwide spread of multiresistant Enterobacteriaceae. J. Antimicrob. Chemother. 67:2090-2100. http://dx.doi.org/10.1093/jac/dks214.
28. Laupland KB, Church DL, Vidakovich J, Mucenski M, Pitout JD. 2008. Community-onset extended-spectrum beta-lactamase (ESBL) producing Escherichia coli: importance of international travel. J. Infect. 57:441-448. http://dx.doi.org/10.1016/j.jinf.2008.09.034.
29. Søraas A, Sundsfjord A, Sandven I, Brunborg C, Jenum PA. 2013. Risk factors for community-acquired urinary tract infections caused by ESBL-producing enterobacteriaceae - a case-control study in a low prevalence country. PLoS One 8:e69581. http://dx.doi.org/10.1371/journal.pone.0069581.
30. Rogers BA, Kennedy KJ, Sidjabat HE, Jones M, Collignon P, Paterson DL. 2012. Prolonged carriage of resistant E. coli by returned travellers: clonality, risk factors and bacterial characteristics. Eur. J. Clin. Microbiol. Infect. Dis. 31:2413-2420. http://dx.doi.org/10.1007/s10096-012-1584-z.
31. Nicolas-Chanoine MH, Jarlier V, Robert J, Arlet G, Drieux L, Leflon-Guibout V, Laouenan C, Larroque B, Caro V, Mentre F. 2012. Patient's origin and lifestyle associated with CTX-M-producing Escherichia coli: a case-control-control study. PLoS One 7:e30498. http://dx.doi.org/10.1371/ journal.pone.0030498.
32. Hilty M, Betsch BY, Bogli-Stuber K, Heiniger N, Stadler M, Kuffer M, Kronenberg A, Rohrer C, Aebi S, Endimiani A, Droz S, Muhlemann K. 2012. Transmission dynamics of extended-spectrum beta-lactamase-producing Enterobacteriaceae in the tertiary care hospital and the household setting. Clin. Infect. Dis. 55:967-975. http://dx.doi.org/10.1093/cid/cis581.
33. Freeman JT, Williamson DA, Heffernan H, Smith M, Bower JE, Roberts SA. 2012. Comparative epidemiology of CTX-M-14 and CTX-M-15 producing Escherichia coli: association with distinct demographic groups in the community in New Zealand. Eur. J. Clin. Microbiol. Infect. Dis. 31:2057-2060. http://dx.doi.org/10.1007/s10096-011-1540-3.
34. Rodríguez-Baño J, Miró E, Villar M, Coelho A, Gozalo M, Borrell N, Bou G, Conejo MC, Pomar V, Aracil B, Larrosa N, Agüero J, Oliver A, Fernández A, Oteo J, Pascual A, Navarro F. 2012. Colonisation and infection due to Enterobacteriaceae producing plasmid-mediated AmpC beta-lactamases. J. Infect. 64:176-183. http://dx.doi.org/10.1016/j.jinf.2011. 11.016.
35. Rogers BA, Sidjabat HE, Paterson DL. 2011. Escherichia coli O25b-ST131: a pandemic, multiresistant, community-associated strain. J. Antimicrob. Chemother. 66:1-14. http://dx.doi.org/10.1093/jac/dkq415.
36. Rogers BA, Doi Y. 2013. Who is leading this dance? Understanding the spread of Escherichia coli sequence type 131. Infect. Control Hosp. Epidemiol. 34:370-372. http://dx.doi.org/10.1086/669874.
37. Melzer M, Petersen I. 2007. Mortality following bacteraemic infection caused by extended spectrum beta-lactamase (ESBL) producing E. coli compared to non-ESBL producing E. coli. J. Infect. 55:254-259. http://dx.doi.org/10.1016/j. jinf.2007.04.007. (Pubitemid 47244918)
38. Courpon-Claudinon A, Lefort A, Panhard X, Clermont O, Dornic Q, Fantin B, Mentre F, Wolff M, Denamur E, Branger C. 2011. Bacteraemia caused by third-generation cephalosporin-resistant Escherichia coli in France: prevalence, molecular epidemiology and clinical features. Clin. Microbiol. Infect. 17:557-565. http://dx.doi.org/10.1111/j.1469-0691.2010.03298.x.
39. Pitout JD, Gregson DB, Campbell L, Laupland KB. 2009. Molecular characteristics of extended-spectrum-beta-lactamase-producing Escherichia coli isolates causing bacteremia in the Calgary Health Region from 2000 to 2007: emergence of clone ST131 as a cause of community-acquired infections. Antimicrob. Agents Chemother. 53:2846-2851. http://dx.doi.org/10.1128/AAC.00247- 09.
40. Rodríguez-Baño J, Navarro MD, Romero L, Martínez- Martínez L, Muniain MA, Perea EJ, Pérez-Cano R, Pascual A. 2004. Epidemiology and clinical features of infections caused by extended-spectrum beta-lactamase-producing Escherichia coli in nonhospitalized patients. J. Clin. Microbiol. 42:1089-1094. http://dx.doi.org/10.1128/JCM.42.3.1089-1094.2004. (Pubitemid 38332830)
41. Kennedy KJ, Roberts JL, Collignon PJ. 2008. Escherichia coli bacteraemia in Canberra: incidence and clinical features. Med. J. Aust. 188:209-213.
42. Kaye KS, Harris AD, Samore M, Carmeli Y. 2005. The case-case-control study design: addressing the limitations of risk factor studies for antimicrobial resistance. Infect. Control Hosp. Epidemiol. 26:346-351. http://dx.doi.org/10.1086/502550. (Pubitemid 40545579)
43. Stuart RL, Kotsanas D, Webb B, Vandergraaf S, Gillespie EE, Hogg GG, Korman TM. 2011. Prevalence of antimicrobial-resistant organisms in residential aged care facilities. Med. J. Aust. 195:530-533. http://dx.doi.org/10.5694/ mja11.10724.
44. Banerjee R, Johnston B, Lohse C, Porter SB, Clabots C, Johnson JR. 2013. Escherichia coli sequence type 131 is a dominant, antimicrobial-resistant clonal group associated with healthcare and elderly hosts. Infect. Control Hosp. Epidemiol. 34:361-369. http://dx.doi.org/10.1086/669865.
45. Rooney PJ, O'Leary MC, Loughrey AC, McCalmont M, Smyth B, Donaghy P, Badri M, Woodford N, Karisik E, Livermore DM. 2009. Nursing homes as a reservoir of extended-spectrum beta-lactamase (ESBL)-producing ciprofloxacin-resistant Escherichia coli. J. Antimicrob. Chemother. 64:635-641. http://dx.doi.org/10. 1093/jac/dkp220.